Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin

Cornelius J. Clancy, Liang Chen, Jae H. Hong, Shaoji Cheng, Binghua Hao, Ryan K. Shields, Annie N. Farrell, Yohei Doi, Yanan Zhao, David S. Perlin, Barry N. Kreiswirth, M. Hong Nguyen

研究成果: Article

50 引用 (Scopus)

抄録

Doripenem-colistin exerts synergy against some, but not all, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains in vitro. We determined if doripenem MICs and/or ompK36 porin gene mutations impacted the responses of 23 sequence type 258 (ST258), KPC-2-producing strains to the combination of doripenem (8 μg/ml) and colistin (2 μg/ml) during time-kill assays. The median doripenem and colistin MICs were 32 and 4 μg/ml. Doripenem MICs did not correlate with KPC-2 expression levels. Five and 18 strains had wild-type and mutant ompK36, respectively. The most common mutations were IS5 promoter insertions (n = 7) and insertions encoding glycine and aspartic acid at amino acid (aa) positions 134 and 135 (ins aa134-135 GD; n = 8), which were associated with higher doripenem MICs than other mutations or wild-type ompK36 (all P values ≤ 0.04). Bactericidal activity (24 h) was achieved by doripenem-colistin against 12%, 43%, and 75% of ins aa134-135 GD, IS5, and wild-type/other mutants, respectively (P = 0.04). Doripenem-colistin was more active in time-kill studies than colistin at 12 and 24 h if the doripenem MIC was ≤8 μg/ml (P = 0.0007 and 0.09, respectively), but not if the MIC was >8 μg/ml (P = 0.10 and 0.16). Likewise, doripenem-colistin was more active at 12 and 24 h against the wild type/other mutants than ins aa134-135 GD or IS5 mutants (P = 0.007 and 0.0007). By multivariate analysis, the absence of ins aa134-135 GD or IS5 mutations was the only independent predictor of doripenem-colistin responses at 24 h (P = 0.002). In conclusion, ompK36 genotypes identified ST258 KPC-K. pneumoniae strains that were most likely to respond to doripenem-colistin.

元の言語English
ページ(範囲)5258-5265
ページ数8
ジャーナルAntimicrobial agents and chemotherapy
57
発行部数11
DOI
出版物ステータスPublished - 01-11-2013

Fingerprint

doripenem
Colistin
Porins
Klebsiella pneumoniae
Mutation
Genes
Klebsiella pneumoniae carbapenemase-2

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

Clancy, Cornelius J. ; Chen, Liang ; Hong, Jae H. ; Cheng, Shaoji ; Hao, Binghua ; Shields, Ryan K. ; Farrell, Annie N. ; Doi, Yohei ; Zhao, Yanan ; Perlin, David S. ; Kreiswirth, Barry N. ; Nguyen, M. Hong. / Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. :: Antimicrobial agents and chemotherapy. 2013 ; 巻 57, 番号 11. pp. 5258-5265.
@article{cf31b14986744e258c107a936d307264,
title = "Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin",
abstract = "Doripenem-colistin exerts synergy against some, but not all, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains in vitro. We determined if doripenem MICs and/or ompK36 porin gene mutations impacted the responses of 23 sequence type 258 (ST258), KPC-2-producing strains to the combination of doripenem (8 μg/ml) and colistin (2 μg/ml) during time-kill assays. The median doripenem and colistin MICs were 32 and 4 μg/ml. Doripenem MICs did not correlate with KPC-2 expression levels. Five and 18 strains had wild-type and mutant ompK36, respectively. The most common mutations were IS5 promoter insertions (n = 7) and insertions encoding glycine and aspartic acid at amino acid (aa) positions 134 and 135 (ins aa134-135 GD; n = 8), which were associated with higher doripenem MICs than other mutations or wild-type ompK36 (all P values ≤ 0.04). Bactericidal activity (24 h) was achieved by doripenem-colistin against 12{\%}, 43{\%}, and 75{\%} of ins aa134-135 GD, IS5, and wild-type/other mutants, respectively (P = 0.04). Doripenem-colistin was more active in time-kill studies than colistin at 12 and 24 h if the doripenem MIC was ≤8 μg/ml (P = 0.0007 and 0.09, respectively), but not if the MIC was >8 μg/ml (P = 0.10 and 0.16). Likewise, doripenem-colistin was more active at 12 and 24 h against the wild type/other mutants than ins aa134-135 GD or IS5 mutants (P = 0.007 and 0.0007). By multivariate analysis, the absence of ins aa134-135 GD or IS5 mutations was the only independent predictor of doripenem-colistin responses at 24 h (P = 0.002). In conclusion, ompK36 genotypes identified ST258 KPC-K. pneumoniae strains that were most likely to respond to doripenem-colistin.",
author = "Clancy, {Cornelius J.} and Liang Chen and Hong, {Jae H.} and Shaoji Cheng and Binghua Hao and Shields, {Ryan K.} and Farrell, {Annie N.} and Yohei Doi and Yanan Zhao and Perlin, {David S.} and Kreiswirth, {Barry N.} and Nguyen, {M. Hong}",
year = "2013",
month = "11",
day = "1",
doi = "10.1128/AAC.01069-13",
language = "English",
volume = "57",
pages = "5258--5265",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

Clancy, CJ, Chen, L, Hong, JH, Cheng, S, Hao, B, Shields, RK, Farrell, AN, Doi, Y, Zhao, Y, Perlin, DS, Kreiswirth, BN & Nguyen, MH 2013, 'Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin', Antimicrobial agents and chemotherapy, 巻. 57, 番号 11, pp. 5258-5265. https://doi.org/10.1128/AAC.01069-13

Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. / Clancy, Cornelius J.; Chen, Liang; Hong, Jae H.; Cheng, Shaoji; Hao, Binghua; Shields, Ryan K.; Farrell, Annie N.; Doi, Yohei; Zhao, Yanan; Perlin, David S.; Kreiswirth, Barry N.; Nguyen, M. Hong.

:: Antimicrobial agents and chemotherapy, 巻 57, 番号 11, 01.11.2013, p. 5258-5265.

研究成果: Article

TY - JOUR

T1 - Mutations of the ompK36 porin gene and promoter impact responses of sequence Type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin

AU - Clancy, Cornelius J.

AU - Chen, Liang

AU - Hong, Jae H.

AU - Cheng, Shaoji

AU - Hao, Binghua

AU - Shields, Ryan K.

AU - Farrell, Annie N.

AU - Doi, Yohei

AU - Zhao, Yanan

AU - Perlin, David S.

AU - Kreiswirth, Barry N.

AU - Nguyen, M. Hong

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Doripenem-colistin exerts synergy against some, but not all, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains in vitro. We determined if doripenem MICs and/or ompK36 porin gene mutations impacted the responses of 23 sequence type 258 (ST258), KPC-2-producing strains to the combination of doripenem (8 μg/ml) and colistin (2 μg/ml) during time-kill assays. The median doripenem and colistin MICs were 32 and 4 μg/ml. Doripenem MICs did not correlate with KPC-2 expression levels. Five and 18 strains had wild-type and mutant ompK36, respectively. The most common mutations were IS5 promoter insertions (n = 7) and insertions encoding glycine and aspartic acid at amino acid (aa) positions 134 and 135 (ins aa134-135 GD; n = 8), which were associated with higher doripenem MICs than other mutations or wild-type ompK36 (all P values ≤ 0.04). Bactericidal activity (24 h) was achieved by doripenem-colistin against 12%, 43%, and 75% of ins aa134-135 GD, IS5, and wild-type/other mutants, respectively (P = 0.04). Doripenem-colistin was more active in time-kill studies than colistin at 12 and 24 h if the doripenem MIC was ≤8 μg/ml (P = 0.0007 and 0.09, respectively), but not if the MIC was >8 μg/ml (P = 0.10 and 0.16). Likewise, doripenem-colistin was more active at 12 and 24 h against the wild type/other mutants than ins aa134-135 GD or IS5 mutants (P = 0.007 and 0.0007). By multivariate analysis, the absence of ins aa134-135 GD or IS5 mutations was the only independent predictor of doripenem-colistin responses at 24 h (P = 0.002). In conclusion, ompK36 genotypes identified ST258 KPC-K. pneumoniae strains that were most likely to respond to doripenem-colistin.

AB - Doripenem-colistin exerts synergy against some, but not all, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains in vitro. We determined if doripenem MICs and/or ompK36 porin gene mutations impacted the responses of 23 sequence type 258 (ST258), KPC-2-producing strains to the combination of doripenem (8 μg/ml) and colistin (2 μg/ml) during time-kill assays. The median doripenem and colistin MICs were 32 and 4 μg/ml. Doripenem MICs did not correlate with KPC-2 expression levels. Five and 18 strains had wild-type and mutant ompK36, respectively. The most common mutations were IS5 promoter insertions (n = 7) and insertions encoding glycine and aspartic acid at amino acid (aa) positions 134 and 135 (ins aa134-135 GD; n = 8), which were associated with higher doripenem MICs than other mutations or wild-type ompK36 (all P values ≤ 0.04). Bactericidal activity (24 h) was achieved by doripenem-colistin against 12%, 43%, and 75% of ins aa134-135 GD, IS5, and wild-type/other mutants, respectively (P = 0.04). Doripenem-colistin was more active in time-kill studies than colistin at 12 and 24 h if the doripenem MIC was ≤8 μg/ml (P = 0.0007 and 0.09, respectively), but not if the MIC was >8 μg/ml (P = 0.10 and 0.16). Likewise, doripenem-colistin was more active at 12 and 24 h against the wild type/other mutants than ins aa134-135 GD or IS5 mutants (P = 0.007 and 0.0007). By multivariate analysis, the absence of ins aa134-135 GD or IS5 mutations was the only independent predictor of doripenem-colistin responses at 24 h (P = 0.002). In conclusion, ompK36 genotypes identified ST258 KPC-K. pneumoniae strains that were most likely to respond to doripenem-colistin.

UR - http://www.scopus.com/inward/record.url?scp=84885909214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885909214&partnerID=8YFLogxK

U2 - 10.1128/AAC.01069-13

DO - 10.1128/AAC.01069-13

M3 - Article

VL - 57

SP - 5258

EP - 5265

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -